MUHU Health
EnglishObtenga una evaluación gratuita

Empiece por la afección que conoce.

Una inquietud sobre diabetes, función renal, salud hepática u otro órgano tiene sus propios antecedentes y plan de atención. Cuéntenos el diagnóstico de su profesional clínico, cualquier etapa conocida o cambio reciente y la pregunta que quiere resolver.

Ilustración en acuarela de la vida cotidiana en la región montañosa de Colombia

Comparta la historia detrás de los resultados.

La interpretación de su especialista, los informes anteriores y actuales, los medicamentos y el tratamiento existente ayudan a nuestro equipo médico a comprender la evolución y las prioridades. Si el diagnóstico no está claro, díganoslo y le explicaremos qué evaluación sería útil.

Su diagnóstico

¿Qué diagnóstico le han comunicado?

Cambios con el tiempo

Comparta resultados clave y cambios recientes.

Atención actual

Cuéntenos sobre sus medicamentos y tratamiento actual.

Inquietudes que nos comparten:

Angina y problemas circulatorios

Comparta su diagnóstico de angina, angina refractaria, aterosclerosis o enfermedad arterial periférica, junto con la atención cardiológica que recibe actualmente.

Miocardiopatía e insuficiencia cardíaca

Cuéntenos sobre la miocardiopatía o la insuficiencia cardíaca, sus resultados de exámenes, la atención actual y los cambios que afectan su vida diaria.

Antecedente de infarto de miocardio

Un infarto previo forma parte de los antecedentes cardiovasculares y del plan de atención continua de la persona.

Enfermedad hepática

Comparta su diagnóstico de hígado graso, fibrosis hepática, cirrosis, hepatitis o insuficiencia hepática, junto con los informes pertinentes y su atención actual.

Enfermedad renal

Incluya informes sobre lesión renal aguda, enfermedad renal crónica, insuficiencia renal, nefropatía diabética, nefritis lúpica o síndrome nefrótico, y el plan actual de su especialista.

Fibrosis pulmonar y SDRA

Comparta su diagnóstico de fibrosis pulmonar o síndrome de dificultad respiratoria aguda (SDRA), los informes pertinentes y el seguimiento que recibe actualmente.

Asma

Una afección en la que la inflamación y el estrechamiento de las vías respiratorias pueden causar síntomas respiratorios.

EPOC

Enfermedad pulmonar obstructiva crónica, un grupo de afecciones pulmonares que restringen el flujo de aire.

Diabetes y metabolismo

Cuéntenos sobre la diabetes tipo 1 o tipo 2, las complicaciones diabéticas o la resistencia a la insulina, incluidos sus resultados recientes, medicamentos y evolución.

Todos los tratamientos que ofrecemos están respaldados por estudios clínicos.Consulte la investigación

Salud metabólica y de los órganos

145 estudios
  1. Causal effects of inflammatory cytokines on cardiovascular diseases: Insights from genetic evidence. (2024)
  2. Editorial: Application of stem cells in the treatment of myocardial infarction. (2023)
  3. The Safety and Efficacy of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Patients With Heart Failure and Myocardial Infarction: A Meta-Analysis of Clinical Trials. (2023)
  4. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing. (2023)
  5. Stem cell-based therapy in cardiac repair after myocardial infarction: Promise, challenges, and future directions. (2024)
  6. Innovative approaches to boost mesenchymal stem cells efficacy in myocardial infarction therapy. (2025)
  7. Refractory angina pectoris: a 20-year (2003-2022) bibliometric analysis. (2023)
  8. IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries. (2022)
  9. INOCA/ANOCA: Mechanisms and novel treatments. (2023)
  10. Cell Therapy in the Treatment of Coronary Heart Disease. (2023)
  11. Human Bone Marrow Mesenchymal Stem Cells Promote the M2 Phenotype in Macrophages Derived from STEMI Patients. (2023)
  12. Macrophages after myocardial infarction: Mechanisms for repairing and potential as therapeutic approaches. (2024)
  13. A Review of Therapeutic Approaches for Post-Infarction Left Ventricular Remodeling. (2024)
  14. Biomimetic nanomaterials in myocardial infarction treatment: Harnessing bionic strategies for advanced therapeutics. (2024)
  15. Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy. (2025)
  16. The recent advances in cell delivery approaches, biochemical and engineering procedures of cell therapy applied to coronary heart disease. (2023)
  17. Microvascular Obstruction Identifies a Subgroup of Patients Who Benefit from Stem Cell Therapy Following ST-Elevation Myocardial Infarction. (2023)
  18. Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial. (2023)
  19. Exploring Cutting-Edge Approaches to Potentiate Mesenchymal Stem Cell and Exosome Therapy for Myocardial Infarction. (2023)
  20. Cardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction. (2024)
  21. Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment. (2024)
  22. Mid- to long-term efficacy and safety of stem cell therapy for acute myocardial infarction: a systematic review and meta-analysis. (2024)
  23. Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis. (2024)
  24. Healing the Ischaemic Heart: A Critical Review of Stem Cell Therapies. (2023)
  25. Stem Cell Therapy for Myocardial Infarction and Heart Failure: A Comprehensive Systematic Review and Critical Analysis. (2024)
  26. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. (2025)
  27. Exosomal Cargo: Pro-angiogeneic, anti-inflammatory, and regenerative effects in ischemic and non-ischemic heart diseases - A comprehensive review. (2023)
  28. Mesenchymal Stem Cell Therapy for a Better Prognosis of Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2023)
  29. Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomized controlled trials. (2024)
  30. The Use of Hematopoietic Stem Cells for Heart Failure: A Systematic Review. (2024)
  31. Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs. (2024)
  32. Stem cell therapy for non-ischemic dilated cardiomyopathy: a systematic review and meta-analysis. (2024)
  33. Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study. (2024)
  34. Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (2025)
  35. In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction. (2023)
  36. Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial. (2024)
  37. Exploring the mechanism of atherosclerosis and the intervention of traditional Chinese medicine combined with mesenchymal stem cells based on inflammatory targets. (2023)
  38. Exosomes in Atherosclerosis: Role in the Pathogenesis and Targets for Therapy. (2024)
  39. Stem cell-derived exosome delivery systems for treating atherosclerosis: The new frontier of stem cell therapy. (2024)
  40. Development of stem cell therapy for atherosclerosis. (2023)
  41. Top Five Stories of the Cellular Landscape and Therapies of Atherosclerosis: Current Knowledge and Future Perspectives. (2023)
  42. Emerging Therapeutic and Diagnostic Strategies for Coronary Artery Disease: Current Trends and Future Perspectives. (2024)
  43. The Application of Mesenchymal Stem Cells in Different Cardiovascular Disorders: Ways of Administration, and the Effectors. (2024)
  44. Caught in action: how MSCs modulate atherosclerotic plaque. (2024)
  45. A Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia. (2025)
  46. Mesenchymal Stem Extracellular Vesicles in Various Respiratory Diseases: A New Opportunity. (2024)
  47. Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects. (2024)
  48. Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic. (2024)
  49. Human umbilical cord mesenchymal stem cell-derived microvesicles alleviate pulmonary fibrosis by inhibiting monocyte‒macrophage migration through ERK1/2 signaling-mediated suppression of CCL2 expression. (2025)
  50. Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome. (2023)
  51. Mesenchymal stem cells and their derived exosomes for ALI/ARDS: A promising therapy. (2023)
  52. Recent progress in mesenchymal stem cell-based therapy for acute lung injury. (2024)
  53. Umbilical Cord Mesenchymal Stem Cells Could Reduce Lung Damage Caused by H1N1 Influenza Virus Infection. (2025)
  54. Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation. (2025)
  55. Efficacy and safety of mesenchymal stem cell therapy for acute respiratory distress syndrome-a systematic review and meta-analysis. (2024)
  56. hucMSCs treatment prevents pulmonary fibrosis by reducing circANKRD42-YAP1-mediated mechanical stiffness. (2023)
  57. Mesenchymal stem/stromal cells alleviate early-stage pulmonary fibrosis in a uPAR-dependent manner. (2024)
  58. Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects. (2024)
  59. Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Pathogenesis, Biomarkers and Innovative Therapeutic Strategies. (2024)
  60. Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments. (2024)
  61. The Application of Mesenchymal Stem Cell Therapy in Treating Pulmonary Fibrosis: A Scoping Review. (2024)
  62. Microvesicles derived from mesenchymal stem cells: A promising therapeutic strategy for acute respiratory distress syndrome-related pulmonary fibrosis? World J Stem Cells. (2025)
  63. Cell therapy: A beacon of hope in the battle against pulmonary fibrosis. (2025)
  64. Notch Signaling Pathway Interfering as a Possible Asthma Treatment: A Narrative Review. (2025)
  65. Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement. (2023)
  66. Therapeutic potential of mesenchymal stem cell-derived exosomes for allergic airway inflammation. (2024)
  67. Immunomodulatory Effect of Adipose Stem Cell-Derived Extra-Cellular Vesicles on Cytokine Expression and Regulatory T Cells in Patients with Asthma. (2024)
  68. From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy. (2024)
  69. Asthma and stem cell therapy. (2025)
  70. Harnessing the Therapeutic Potential of Stem Cells in the Management of Chronic Obstructive Pulmonary Disease: A Comprehensive Review. (2023)
  71. Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option. (2024)
  72. Stem Cell Transplants Might Boost Lung Function in People With COPD. (2024)
  73. Factors Affecting and Promoting Health-related Quality of Life in Patients With Liver Cirrhosis: An Underestimated Domain in Patient Care. (2024)
  74. Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives. (2025)
  75. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment. (2023)
  76. Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells. (2023)
  77. Editorial: Community series in hepatic immune response underlying liver cirrhosis and portal hypertension, volume II. (2023)
  78. Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside. (2023)
  79. Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease. (2023)
  80. Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions. (2024)
  81. Innovative mesenchymal stem cell treatments for fatty liver disease. (2024)
  82. Mesenchymal Stem Cell-Derived Exosomes: Emerging as a Promising Cell-Free Therapeutic Strategy for Autoimmune Hepatitis. (2024)
  83. Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease. (2024)
  84. Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome. (2024)
  85. Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum. (2025)
  86. Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission. (2025)
  87. Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells. (2023)
  88. Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease. (2023)
  89. Use of Mesenchymal Stem Cell Transplantation as a Treatment for Liver Cirrhosis in Animal Models. (2024)
  90. Protein Lactylation Modification and Proteomics Features in Cirrhosis Patients after UC-MSC Treatment. (2023)
  91. Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis. (2023)
  92. Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure. (2023)
  93. Advancements in mesenchymal stem cell therapy for liver cirrhosis: Unveiling origins, treatment mechanisms, and current research frontiers. (2023)
  94. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis. (2023)
  95. Exosomes; a Potential Source of Biomarkers, Therapy, and Cure for Type-1 Diabetes. (2023)
  96. Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies. (2025)
  97. Mesenchymal stem cell therapy for treating the underlying causes of diabetes mellitus and its consequences. (2023)
  98. Transplantation of adipose derived stem cells in diabetes mellitus; limitations and achievements. (2023)
  99. Progress and application of adipose-derived stem cells in the treatment of diabetes and its complications. (2024)
  100. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial. (2023)
  101. Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review. (2023)
  102. Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes. (2023)
  103. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. (2023)
  104. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells. (2023)
  105. Efficacy of umbilical cord-derived mesenchymal stem cells in the treatment of type 2 diabetes assessed by retrospective continuous glucose monitoring. (2023)
  106. Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances. (2023)
  107. Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity. (2023)
  108. Stem Cell Therapy for the Management of Type 1 Diabetes: Advances and Perspectives. (2023)
  109. Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes. (2024)
  110. Advances and challenges of the cell-based therapies among diabetic patients. (2024)
  111. Efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes: a systematic review. (2024)
  112. Evaluation of type 1 diabetes' partial clinical remission after three years of heterologous adipose tissue derived stromal/stem cells transplantation associated with vitamin D supplementation. (2024)
  113. The future of diabetic wound healing: unveiling the potential of mesenchymal stem cell and exosomes therapy. (2024)
  114. Advances in Type 1 Diabetes Mellitus Management in Children. (2024)
  115. Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review. (2024)
  116. The Immunomodulatory effect of exosomes in diabetes: a novel and attractive therapeutic tool in diabetes therapy. (2024)
  117. Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up. (2024)
  118. Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new? Expert Opin Investig Drugs. (2024)
  119. Safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of type 1 and type 2 diabetes mellitus: a systematic review and meta-analysis. (2025)
  120. The Potential of Mesenchymal Stem Cell-Derived Exosomes to Treat Diabetes Mellitus. (2025)
  121. From bench to bedside: future prospects in stem cell therapy for diabetes. (2025)
  122. Stem cells head to the clinic: treatments for cancer, diabetes and Parkinson's disease could soon be here. (2025)
  123. Exploring the role of exosomes in diabetic neuropathy: From molecular mechanisms to therapeutic potential. (2025)
  124. Impacts of stem cells from different sources on wound healing rate in diabetic foot ulcers: a systematic review and meta-analysis. (2025)
  125. Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis. (2025)
  126. Toward a cure for diabetes: iPSC and ESC-derived islet cell transplantation trials. (2024)
  127. Stem cells reverse type 1 diabetes. (2024)
  128. A Cure for Type 1 Diabetes: Are We There Yet? Diabetes Technol Ther. (2025)
  129. Predictive factors that influence the clinical efficacy of umbilical cord-derived mesenchymal stromal cells in the treatment of type 2 diabetes mellitus. (2024)
  130. Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. (2024)
  131. Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34+ cell therapy: A clinical trial. (2024)
  132. Mesenchymal Stem Cell Therapy: Therapeutic Opportunities and Challenges for Diabetic Kidney Disease. (2024)
  133. Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges. (2023)
  134. Narrative Review of Mesenchymal Stem Cell Therapy in Renal Diseases: Mechanisms, Clinical Applications, and Future Directions. (2024)
  135. Advances in the Treatment of Kidney Disorders using Mesenchymal Stem Cells. (2024)
  136. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. (2025)
  137. Safety of Stromal Vascular Fraction Cell Therapy for Chronic Kidney Disease of Unknown Cause (Mesoamerican Nephropathy). (2022)
  138. Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications. (2022)
  139. First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome. (2022)
  140. Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. (2023)
  141. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M Cell) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). (2023)
  142. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. (2023)
  143. Cell therapy in kidney diseases: advancing treatments for renal regeneration. (2024)
  144. Endothelial progenitor cells for diabetic cardiac and kidney disease. (2024)
  145. Emerging Frontiers in acute kidney injury: The role of extracellular vesicles. (2025)

Aclare el siguiente paso antes de viajar

Le explicaremos si una evaluación es pertinente y qué información ayuda. Si podemos ayudarle, su propuesta escrita relacionará el tratamiento con su situación y detallará las citas, el seguimiento y el costo completo.

Evaluación clínica

Revisamos su diagnóstico, informes y atención actual para confirmar si existe un enfoque pertinente.

Tratamiento definido

Su propuesta identifica el tratamiento, la preparación y las citas propuestas para su situación.

Seguimiento planificado

Las citas de seguimiento y el control de la recuperación se incluyen en su propuesta para que sepa qué esperar.

Un total por escrito

Una propuesta escrita detalla el precio completo del tratamiento. Alojamiento, apoyo y servicios opcionales por separado.

Obtenga una evaluación gratuita